NDAINTRAVENOUSSOLUTION
Approved
May 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
5
Mechanism of Action
Cytochrome P450 3A Inducers
Pharmacologic Class:
Orthopoxvirus VP37 Envelope Wrapping Protein Inhibitor
Clinical Trials (5)
Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders
Started Jun 2022
44 enrolled
Smallpox
Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS
Started Apr 2022
100 enrolled
Smallpox
Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Days
Started Mar 2022
467 enrolled
Smallpox
A Phase 4, Observational Field Study to Evaluate TPOXX in Patients With Smallpox
Started Jan 2020
0Smallpox
Safety, Tolerability and PK of TPOXX in Adults Weighing More Than 120 KG
Started Jul 2019
34 enrolled
Smallpox
Loss of Exclusivity
LOE Date
Sep 4, 2031
67 months away
Patent Expiry
Sep 4, 2031
Company
Siga
NEW YORK, NY